Healx
Latest news and articles
Filter
All
News
In the media
Events
News & Opinion
Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial
News & Opinion
Remembering Dr. Neil T. Thompson
News & Opinion
Video: Working together to end Neurofibromatosis - speech at the CTF Patient Summit 2024
News & Opinion
Healx to receive investment from Children’s Tumor Foundation to advance Neurofibromatosis Type 1 treatments
News & Opinion
Lig3DLens: An open source ligand-based 3D virtual screening toolbox
News & Opinion
Healx receives US Orphan Drug Designation for its AI-discovered treatment of Neurofibromatosis Type 1 (NF1)
In the media
The US AI Bill Of Rights should kickstart the debate on bias in AI
In the media
The challenges of identifying rare diseases
In the media
Rare Disease Day: Bruce Bloom on technology & AI
News & Opinion
Our first Wikipedia Edit-a-thon
In the media
Andrew Watson, Vice President of AI and R & D at Healx – Interview Series
In the media
England’s Rare Diseases Action Plan Needs AI To Succeed
In the media
European or not, make sure your AI business sticks to EU data laws
News & Opinion
Healx presents data on AI-predicted therapies for fragile X syndrome at the National Fragile X Foundation (NFXF) International Conference 2022
In the media
EU-Startups Podcast | Episode 26: Healx Co-Founder and CEO, Dr Tim Guillams!
In the media
Healx opens lab at Chesterford Research Park
News & Opinion
AI-powered drug discovery company Healx opens new labs at Chesterford Research Park
In the media
Building a start-up? You need to think about your platform foundations
In the media
Life Sci AI: The Podcast - Using AI in Drug Discovery for Rare Diseases
In the media
Policy Must Keep Pace with Technology if we are to Reap the Benefits of AI Drug Discovery for Rare Diseases
In the media
The Ethical Adoption Of AI In Healthcare Requires A Global Effort, Now More Than Ever
In the media
Healx launch orphan disease research call for academics through IN-PART
News & Opinion
AI promises a new future of drug discovery for rare diseases
In the media
AI Widens Search Spaces and Promises More Hits in Drug Discovery
In the media
Tech For Good Podcast: Tim Guilliams
News & Opinion
Nathan Brown joins Healx as Director of Digital Chemistry
In the media
Founder in Five: Q&A with Healx CEO Tim Guilliams
In the media
Healx’s AI Platform Draws Novel Connections in Myriad Rare Diseases
In the media
Healx - hunting new drugs with AI
In the media
Ovid pens deal to offload former lead program, positioning Healx to write new chapter in fragile X
News & Opinion
Healx and Ovid Therapeutics Enter Strategic Partnership
In the media
Bruce Bloom, our Chief Collaborations Officer, joins the Rare Disease Company Coalition leadership team
In the media
Healx: innovating drug discovery with AI and data
In the media
Teaching old drugs new tricks to treat COVID-19
In the media
Healx joins The Rare Disease Company Coalition
News & Opinion
Healx appoints Gillian Bonthron as Chief Finance Officer
In the media
How third-generation drug discovery is transforming rare disease treatment development
In the media
Europe’s AI laws will cost companies a small fortune – but the payoff is trust
In the media
Digital technology takes healthcare to the future
In the media
Dr. Tim Guilliams, Co-founder of AI Drug Development Company, Healx on Going From Startup CxO to Scale-up CxO
News & Opinion
Healx pledges $25,000 to AKU Society patient registry campaign
In the media
Clinical Trials Expand For AI-Designed Drug To Treat Fragile X Syndrome (Forbes)
In the media
UK startup Healx to begin clinical trial on repositioned drug for Fragile X Syndrome
News & Opinion
Healx receives IND and Orphan Drug Designation for fragile X clinical trial
In the media
Healx is solving a problem for 400m people by repurposing medicine
News & Opinion
Healx launches AI-powered indication expansion partnership with Ono Pharmaceutical Co. Ltd.
In the media
What we can learn about treating rare diseases from Viagra
In the media
How to treat rare diseases with existing drugs — with Meri Williams, CTO of Healx
In the media
The Post-Covid Future of AI for Drug Development
In the media
12 Clusters of Tech Report: East of England
News & Opinion
Healx appoints ex-Dyson lead, Andrew Watson, as VP of Artificial Intelligence
In the media
Using AI to uncover rare diseases
News & Opinion
Healx launches partnership with Ataxia UK and FARA to find treatments for rare neurodegenerative condition
In the media
AI in Drug Discovery Starts to Live Up to Hype
In the media
Healx: How AI is rewriting the economics of rare disease drug discovery
In the media
One year on: How AI can supercharge the healthcare of the future
In the media
Healx and PKD Charity use AI to find cures for rare kidney diseases
News & Opinion
Healx and the PKD Charity collaborate to apply AI to the discovery of novel treatments for rare kidney diseases
In the media
Rare Disease Day 2021 Radio Blast
In the media
5 things you need to know about growing a tech team under Covid-19
In the media
Healx partners with Mission: Cure
News & Opinion
Healx teams up with Mission: Cure to discover and advance the world’s first treatments for chronic pancreatitis
In the media
Building tech teams
News & Opinion
Healx’s Rare Treatment Accelerator 2.0 opens to unlock the power of repurposed drugs for rare diseases
In the media
Meri Williams: Driving tech strategy at a start-up using AI for drug discovery
In the media
How AI is offering hope to millions with rare diseases
In the media
Tech.eu Podcast #187: Nvidia + Arm, Klarna’s funding, interview with Meri Williams of Healx
In the media
CTO Talk: Q&A with Healx’s Meri Williams
News & Opinion
Interview with Dr Allyson Berent, Chief Scientific Officer at the Foundation for Angelman Syndrome Therapeutics
In the media
Healx uses AI to find drugs for Angelman Syndrome
In the media
Digital Health 150: The Digital Health Startups Transforming The Future Of Healthcare
News & Opinion
Healx teams up with the Foundation for Angelman Syndrome Therapeutics to accelerate novel treatments towards the clinic
News & Opinion
Q+A with Dr Kate Adcock, Director of Research and Innovation at Muscular Dystrophy UK
News & Opinion
Healx and Muscular Dystrophy UK join forces to find new treatments for rare muscle-wasting diseases
In the media
Healx uses AI platform to develop treaments for COVID 19
In the media
Meet Meri Williams, the super CTO
News & Opinion
Meri Williams joins Healx as Chief Technology Officer
In the media
AI used in fight against COVID-19
In the media
How AI is fighting COVID-19: the companies using intelligent tech to find new drugs
In the media
AI fights back against Coronavirus
In the media
Healx uses AI to help in COVID 19 treaatments
In the media
Healx develops NF therapies with together with CTF
News & Opinion
Healx partners with Children’s Tumor Foundation to progress neurofibromatosis treatments; recruits patient advocate to lead collaborative drug discovery efforts
News & Opinion
Healx using artificial intelligence to find combination drug treatments for COVID-19
In the media
Promoting #EachforEqual this International Women’s Day
News & Opinion
Healx announces first three Rare Treatment Accelerator partnerships
In the media
Repurposing drugs to fight cancer (New York Times)
News & Opinion
Healx appoints Dr Anthony Hall as Chief Medical Officer
In the media
Healx join forces with Boehringer for neurological disease therapy
In the media
Boehringer partners with Healx for AI-based drug discovery
In the media
Boehringer Ingelheim pairs with AI firm Healx to repurpose assets for rare neurological disorders
News & Opinion
Healx joins forces with Boehringer Ingelheim to discover new treatment approaches for rare neurological diseases
In the media
Healx dedicates £20M to rare treatment accelerator
In the media
AI startup Healx looks to find repurposable drugs for rare diseases
In the media
Healx announces Rare Treatment Accelerator
News & Opinion
Healx commits $20 million to launch Rare Treatment Accelerator programme; Appoints Dr Bruce Bloom as Chief Collaboration Officer to lead initiative
News & Opinion
Michale Bouskila-Chubb recognised in 50 Movers and Shakers in BioBusiness Report
News & Opinion
Healx scientists present two new papers at EMNLP 2019 in Hong Kong
In the media
Channeling the power of AI into personalising medicine
In the media
Healx raises money to trial AI-discovered treatments
In the media
Healx raises $56m Series B to use AI to find treatments for rare diseases
In the media
Months after $10m Series A, rare disease AI upstart Healx hauls in $56m in fresh funding
News & Opinion
Healx secures $56m in Series B financing, launches global accelerator programme for rare diseases
In the media
AI for drug repurposing: interview with Dr Ian Roberts
In the media
Healx in the media
News & Opinion
Healx partners with the ICR to develop potential new AI-derived treatments for rare childhood cancer, DIPG
In the media
How women can make the most of the tech boom
In the media
UK drug discovery startup Healx taps GSK, Astex alum as CSO
News & Opinion
Dr Neil Thompson Appointed CSO of Healx to spearhead drug discovery expansion
In the media
Dr Tim Guilliams - Profile
In the media
How machines could mine forgotten data
In the media
25 European medtech and life sciences start-ups to watch in 2019
In the media
Maserati Top 100: Celebrating 2019's Innovators
In the media
How a medical tech company is using AI to cure rare diseases
In the media
Scientists on a mission to cure rare diseases
In the media
Healx and Boston Children's Hospital join forces
News & Opinion
Healx pushing new drug development model in rare diseases with Barth Syndrome Foundation
In the media
Healx and ICR to develop AI-derived treatments for rare childhood cancer
In the media
Ahead of the curve, ahead of the cure
In the media
10 cool start-ups from Cambridge to watch
In the media
Kate Hilyard named as Chief Operating Officer
News & Opinion
Healx welcomes Kate Hilyard, leading pharma executive, to drive the integration of AI with drug discovery for rare diseases
In the media
Funds raised by Viagra co-founder to tackle rare diseases
In the media
Healx secures $10 million Series A to treat rare diseases
In the media
Healx lands $10m Series A to accelerate drug discovery
News & Opinion
Healx raises $10m as investors back AI to find rare disease treatments faster
News & Opinion
Global investors engage in potential Series A
News & Opinion
Healx data scientist wins poster prize for finding new links between rare diseases
News & Opinion
Healx scientist publishes paper predicting effectiveness of combinations of antibiotics
News & Opinion
Healx listed as a Leading Global Innovator in 'Disrupt 100' list
News & Opinion
Healx CEO to speak at Milken Institute Global Conference
News & Opinion
Healx celebrate 3 years of rare disease drug repurposing
News & Opinion
Healx: Key player in Global Drug Repurposing Open Call
News & Opinion
Invitation to support cancer prevention
News & Opinion
Healx CEO meets HM Queen Elizabeth II
In the media
The Killer 50 The 50 hottest disruptive technology companies
News & Opinion
The hunt for a new treatment for neuroblastoma
News & Opinion
Healx CEO gives opening keynote at Orphan Drug Conference
News & Opinion
Healx CSO presents results at CDKL5 Forum conference
News & Opinion
Hermann Hauser KBE backs Healx to combat rare diseases
News & Opinion
Healx announces £1.5m investment led by Jonathan Milner
News & Opinion
Healx wins Cambridge Graduate Business of the Year!
News & Opinion
Healx finalists of Pitch@Palace
In the media
Using genomic signatures to match best drugs for rare disease patients
News & Opinion
Drug repurposing webinar, 16 February
News & Opinion
Healx launch project with aPODD to identify new treatment for medulloblastoma
News & Opinion
New economics for old drugs
News & Opinion
Healx Chair publishes in Nature Reviews Drug Discovery
News & Opinion
Personalised medicine: putting patients at the centre
News & Opinion
Technology provides hope for rare diseases
News & Opinion
Chairing Boston Repurposing Summit
News & Opinion
Healx supports Cambridge Rare Disease Summit 2015
News & Opinion
Healx awarded Life Science Business of the Year
In the media
Rare disease pioneer completes £300k seed round
In the media
Cambridge startup launches rare disease network
In the media
Cambridge startup hopes to find cure for US boy’s rare disease